PSFK’s Trending Topic: Top Stories This Week That Have Nothing To Do With CES
Wearable tech and quantified self gadgets are not the only ones making waves this week.
Thanks to the Consumer Electronics Show this week, we’ve been bombarded with more wearable tech and quantified self gadgets than we have body parts to track. From a 2-in-1 simplified chopstick set to a pill that can correct less-than-perfect pitch, here are the top stories from this week.
Oki Sato of the Japanese design company Nendo, in collaboration with chopsticks manufacturer Hashikura Matsukan, created a simplified version of the chopsticks. The kamiai chopsticks are embedded with a magnet so that they snap together as one piece. Rassen chopsticks are separated into two for eating and joined together when not in use.
During the Super Bowl next month, clothing retail company H&M will run a 30-second ad where viewers can purchase items from David Beckham’s new collection directly from their TVs. The campaign is made possible through Delivery Agent’s TV-commerce platform, which is compatible with Samsung Smart’s latest models.
Social Print Studio created the Vinelodeon, a hand-crank machine that plays Vine videos backwards, fast or slow, and frame by frame. The machine is a white box with a small screen in the middle. The project merges modern technology and vintage design to create something new and unique.
The Reverberating Across The Divide project by Madeline Gannon of Carnegie Mellon University merges the digital with the physical through a custom chronomorphologic modeling environment. The modeling tool uses 3D scanning, 3D modeling, and 3D printing to allow a designer to create digital forms around physical bodies.
Harvard professor of molecular and cellular biology, Takao Hensch, has been testing a drug called valproate, which can restore brain plasticity and facilitate faster skill learning. The drug was given to a group of men who then went through online ear-training exercises for two weeks. Those who took the drug showed significant pitch improvement compared with those who took placebos.